natgillin/translations-raw huggingface dataset:
The first study investigated the effects of Esmya compared with placebo (a dummy treatment) in adult women with heavy uterine bleeding and anaemia.
Jedno je ispitivanje istražilo djelovanje lijeka Esmya u usporedbi s placebom (prividnim liječenjem) u odraslih žena s obilnim krvarenjem iz maternice i anemijom.
The first study involved 1,663 patients whose diabetes was not adequately controlled with the diabetes medicines metformin or metformin and pioglitazone taken by mouth; adding Xultophy to their treatment was compared with adding either of its active substances, insulin degludec or liraglutide.
Prvo je ispitivanje obuhvatilo 1 663 bolesnika čiji dijabetes nije bio primjereno kontroliran lijekovima za liječenje dijabetesa metforminom ili metforminom i pioglitazonom koji se uzimaju peroralno; dodavanje lijeka Xultophy u njihovo liječenje uspoređeno je s dodavanjem jedne od djelatnih tvari lijeka, degludek inzulina ili liraglutida.
The first study involved 17 patients with aHUS who did not respond to or could not be treated with plasma exchange or infusion.
Prvo je ispitivanje obuhvatilo 17 bolesnika s aHUS-om koji nisu odgovorili na liječenje zamjenom plazme ili infuzijom ili nisu mogli biti liječeni na taj način.
The first study involved 2,046 patients with breast cancer.
Prvo je ispitivanje obuhvatilo 2.046 bolesnika s rakom dojke.
The first study involved 22 patients aged 12 years and above, who were given Nuwiq for the treatment of bleeding episodes or to prevent bleeding during surgery.
Prvo je ispitivanje uključivalo 22 bolesnika u dobi od 12 godina i iznad koji su primali Nuwiq za liječenje epizoda krvarenje ili za sprječavanje krvarenja tijekom kirurškog zahvata.
The first study involved 327 previously untreated patients who were infected with hepatitis C virus of genotypes 1, 4, 5 or 6, and who were given Sovaldi together with two other antiviral medicines, peginterferon alfa and ribavirin, for 12 weeks.
Prvo je ispitivanje obuhvatilo 327 prethodno neliječenih bolesnika koji su bili zaraženi virusom hepatitisa C genotipova 1, 4, 5 ili 6 te su primali Sovaldi zajedno s dva druga antivirusna lijeka, peginterferonom alfa i ribavirinom, tijekom 12 tjedana.
The first study involved 35 patients who were given one injection of Ilaris which was repeated after eight weeks.
Prvo je ispitivanje obuhvatilo 35 bolesnika koji su primili jednu injekciju lijeka Ilaris, te drugu nakon osam tjedana.
The first study involved 37 patients and response to treatment was defined as elimination of at least 90% of the giant cells or no progression of the condition after 25 weeks of treatment.
Prvo je ispitivanje obuhvatilo 37 bolesnika, a odgovor na liječenje definiran je eliminacijom najmanje 90% gigantskih stanica ili izostankom napredovanja tumora 25 tjedana nakon liječenja.
The first study involved 40 previously untreated patients with type-1 Gaucher disease, and it looked mainly at the reduction in the size of patients’ spleens.
Prvo ispitivanje obuhvatilo je 40 prethodno neliječenih bolesnika s Gaucherovom bolesti tipa 1, te je istražilo uglavnom smanjivanje veličine slezene bolesnika.
The first study involved 408 women with advanced or metastatic disease that was expressing large quantities of HER2 who had already been treated with anthracyclines, taxanes and trastuzumab but whose disease had got worse or come back.
Prvo je ispitivanje obuhvatilo 408 žena s uznapredovalom ili metastatskom bolešću koja je pokazivala ekspresiju velikih količina HER2, a koje su već liječene antraciklinima, taksanima i trastuzumabom, no čija se bolest pogoršala ili se vratila.
the first study involved 424 patients with locally advanced cancer, looking at the effects of adding Erbitux to radiotherapy; the second study involved 442 patients with recurrent or metastatic cancer, looking at the effects of adding Erbitux to a platinum-based anticancer medicine combination.
prvim su ispitivanjem obuhvaćena 424 bolesnika s lokalno uznapredovanim karcinomom, te je istraženo djelovanje dodavanja lijeka Erbitux u radioterapiju; drugim su ispitivanjem obuhvaćena 442 bolesnika s rekurentnim ili metastatskim karcinomom, te je istraženo djelovanje dodavanja lijeka u Erbitux kombinaciju protutumorskih lijekova baziranih na platini.
The first study involved 616 adults and adolescents given Nucala every 4 weeks for a year, in addition to their regular asthma medicines.
Prvo je ispitivanje uključivalo 616 odraslih osoba i adolescenata koji su uz redovito uzimanje lijekova za astmu uzimali Nucalu svaka 4 tjedna tijekom jedne godine.
The first study involved 63 patients whose spleens had been removed but whose disease was still not controlled.
Prvo ispitivanje obuhvaćalo je 63 bolesnika kojima je odstranjena slezena, ali čija bolest ipak nije bila pod kontrolom.
The first study involved 724 patients with hormone receptor-positive and HER2/neu-negative advanced breast cancer which had got worse after treatment with letrozole and anastrazole (‘non-steroidal aromatase inhibitors’ cancer medicines).
Prvo je ispitivanje uključivalo 724 bolesnica s uznapredovalim rakom dojke pozitivnim na hormonski receptor i negativnim na HER2/neu koji se pogoršao nakon terapije letrozolom i anastrazolom (lijekovi za liječenje raka „nestereoidni inhibitori aromataze”).
The first study involved 835 adults aged 50 to 64 years who had not previously been vaccinated against invasive disease caused by
Prvo je ispitivanje obuhvatilo 835 odraslih osoba u dobi od 50 do 64 godina, koji su prethodno cijepljeni protiv invazivne bolesti uzrokovane S. pneumoniae.
The first study involved 86 adults with short bowel syndrome due to removal of a large section of the small intestine and who needed parenteral nutrition (nutrients and fluids given directly into a vein) at least three times a week.
Prvo je ispitivanje provedeno na 86 odraslih osoba sa sindromom kratkog crijeva zbog uklanjanja velikog dijela tankog crijeva koji su trebali parenteralnu prehranu (hranjive tvari i tekućine primjenjivani izravno u venu) najmanje triput na tjedan.
The first study involved a total of 2,101 patients who had had a knee replacement operation, and the second involved a total of 3,494 patients who had had a hip replacement.
Prvo je ispitivanje obuhvatilo ukupno 2 101 bolesnika koji su podvrgnuti kirurškoj zamjeni koljena, a drugo je ispitivanje obuhvatilo 3 494 bolesnika koji su podvrgnuti kirurškoj zamjeni kuka.
The first study involved a total of 70 children and young adults aged below 21 years, and the second involved a total of 40 adults and adolescents aged over 16 years.
Prvo je ispitivanje obuhvatilo ukupno 70 djece i mladih osoba mlađih od 12 godina, a drugo je obuhvatilo ukupno 40 odraslih osoba i adolescenata starijih od 16 godina.
The first study involved patients whose disease was not controlled with high doses of corticosteroids.
Prvo ispitivanje obuhvatilo je bolesnike čija se bolest nije mogla kontrolirati visokim dozama kortikosteroida.
The first study involving 418 previously untreated advanced melanoma patients found that patients treated with Opdivo survived longer than patients who received the cancer medicine dacarbazine: 73% of patients treated with Opdivo were alive at 12 months compared with 42% of patients given dacarbazine.
Prvo je ispitivanje obuhvatilo 418 bolesnika s uznapredovalim melanomom koji nisu prije bili liječeni, a pokazalo je da su bolesnici koji su liječeno lijekom Opdivo živjeli duže od onih bolesnika koji su bili liječeni lijekom protiv raka dakarbazinom: 73 % bolesnika koji su liječeni lijekom Opdivo bilo je živo nakon 12 mjeseci u usporedbi s 42 % bolesnika koji su primali dakarbazin.
The first study showed that Relvar Ellipta 92/22 microgram improved average FEV1 by 115 ml more than placebo, while the second study showed that Relvar Ellipta 184/22 microgram improved average FEV1 by 131 ml more than placebo.
Prvo je ispitivanje dokazalo da je Relvar Ellipta od 92/22 mikrograma poboljšao prosječni FEV1 za 115 ml više u odnosu na placebo, dok je drugo ispitivanje dokazalo da je Relvar Ellipta od 184/22 mikrograma poboljšao prosječni FEV1 za 131 ml više u odnosu na placebo.
The first study showed that Revinty Ellipta 92/22 microgram improved average FEV1 by 115 ml more than placebo, while the second study showed that Revinty Ellipta 184/22 microgram improved average FEV1 by 131 ml more than placebo.
Prvo je ispitivanje pokazalo da je lijek Revinty Ellipta od 92/22 mikrograma poboljšao prosječni FEV1 za 115 ml više u odnosu na placebo, dok je drugo ispitivanje pokazalo da je lijek Revinty Ellipta od 184/22 mikrograma poboljšao prosječni FEV1 za 131 ml više u odnosu na placebo.
The first study was in 5,407 patients who had undergone a hip replacement.
Prvo je ispitivanje obuhvatilo 5.407 bolesnika koji su podvrgnuti zamjeni kuka.
The first study, involving 1,065 patients, compared different doses of Simponi with placebo as induction treatment.
U prvom ispitivanju, koje je obuhvatilo 1 065 bolesnika, uspoređene su različite doze lijeka Simponi s placebom kao indukcijskom terapijom.
The first study, which enrolled 82 patients between 2 to 17 years of age, was a randomized, double- blind study comparing caspofungin (50 mg/m2 IV once daily following a 70-mg/m2 loading dose on Day 1 [not to exceed 70 mg daily]) to liposomal amphotericin B (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on liposomal amphotericin B) as empirical therapy in paediatric patients with persistent fever and neutropenia.
Prvo ispitivanje, koje je uključivalo 82 bolesnika u dobi od 2 do 17 godina, bilo je randomizirano, dvostruko slijepo ispitivanje u kojem se kaspofungin (50 mg/m2 i.v. jedanput na dan nakon udarne doze od 70 mg/m2 prvog dana [doza nije smjela biti veća od 70 mg na dan]) uspoređivao s liposomalnim amfotericinom B (3 mg/kg i.v. na dan) u omjeru 2:1 (56 bolesnika primalo je kaspofungin, a 26 liposomalni amfotericin B) u empirijskom liječenju pedijatrijskih bolesnika s perzistentnom vrućicom i neutropenijom.
The first study, which involved 1,279 children, compared M-M-RVAXPRO with a similar vaccine that used albumin from human blood in its production.
Prvo ispitivanje koje je uključivalo 1279 djece uspoređivalo je M-M-RVAXPRO sa sličnim cjepivom koje je koristilo albumin iz ljudske krvi u svojoj proizvodnji.
The first symptoms of low blood sugar usually come on quickly and include the following:
Prvi simptomi niskog šećera u krvi obično nastupaju brzo i uključuju sljedeće:
The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if:
Prvi simptomi koji Vas mogu upozoriti na hipoglikemiju ("upozoravajući simptomi") mogu se promijeniti, biti manje izraženi ili potpuno izostati:
The first symptoms which alert you to hypoglycaemia (“warning symptoms”) may change, be weaker or may be missing altogether if
Prvi simptomi koji Vas mogu upozoriti na hipoglikemiju ("upozoravajući simptomi") mogu se promijeniti, biti manje izraženi ili potpuno izostati:
The first tablet Tasmar is to be taken in the morning together with your other parkinsonian medicine ‘levodopa’.
Prvu tabletu Tasmara trebate uzeti ujutro zajedno s Vašim drugim lijekom za Parkinsonovu bolest ‘levodopom’.
The first time you use ANORO you do not need to check that the inhaler is working properly; it contains previously measured doses and is ready to use straight away.
Kada primjenjujete ANORO po prvi puta, ne morate provjeravati radi li inhalator ispravno; on sadrži prethodno odmjerene doze i odmah je spreman za uporabu.
The first time you use Incruse you do not need to check that the inhaler is working properly; it contains previously measured doses and is ready to use straight away.
Kada primjenjujete Incruse po prvi puta, ne morate provjeravati radi li inhalator ispravno; on sadrži prethodno odmjerene doze i odmah je spreman za uporabu.
The first time you use LAVENTAIR you do not need to check that the inhaler is working properly; it contains previously measured doses and is ready to use straight away.
Kada primjenjujete LAVENTAIR po prvi puta, ne morate provjeravati radi li inhalator ispravno; on sadrži prethodno odmjerene doze i odmah je spreman za uporabu.
The first treatment course should start during the first week of menstruation.
Prvi ciklus liječenja treba početi tijekom prvog tjedna menstruacije.
The first two injections should be given at the elected date and the two other injections should preferably be given 3 weeks after.
Prve dvije injekcije trebate primiti odabranog datuma, a druge dvije bi trebali dobiti po mogućnosti 3 tjedana nakon toga.
The first two numbers indicate the month; the next four numbers indicate the year.
Prve dvije znamenke označavaju mjesec, a sljedeće četiri znamenke označavaju godinu.
The first two studies included a total of 991 patients who had not had an adequate response to methotrexate in the past, and the third included 391 patients who had not had an adequate response to TNF blockers in the past.
Prva dva ispitivanja obuhvatila su ukupno 991 bolesnika koji nisu na odgovarajući način reagirali na metotreksat prilikom ranijih liječenja, a treće je obuhvatilo 391 bolesnika koji su u prošlosti primjereno reagirali na blokatore TNF-a.
The first two studies involved patients whose metastatic disease was being treated for the first time (‘first-line’ treatment): the first study (in 923 patients) and the second study (in 1,401 patients) compared Avastin with placebo (a dummy treatment) when given in combination with chemotherapy.
Prvim dvama ispitivanjima bili su obuhvaćeni bolesnici čija je metastatska bolest liječena po prvi put (terapija „prve linije”): u prvom ispitivanju (923 bolesnika) i drugom ispitivanju (1 401 bolesnik) Avastin je uspoređen s placebom (prividnim liječenjem) i primijenjen u kombinaciji s kemoterapijom.
The first ‘click’ means that the needle has been inserted and the injection has started.
Prvi "klik" znači da je igla ušla pod kožu i da je ubrizgavanje počelo.
The Fisher exact test was used to compare proportions in the Pixuvri and comparator chemotherapeutic groups.
Za usporedbu odnosa u skupini liječenih Pixuvriom i kontrolnoj skupini liječenih drugim kemoterapeutikom korišten je Fischerov egzaktni test.
The five main studies of Sprycel, taken twice a day, involved 515 patients, all of whom had received prior treatment with imatinib and had either failed to respond or become resistant to it.
Pet glavnih ispitivanja lijeka Sprycel, koji je uziman dva puta dnevno, obuhvatilo je 515 bolesnika, koji su svi prethodno primili terapiju imatinibom, a nisu imali odgovor ili su razvili rezistenciju na lijek.
The five organs/tissues with the highest cumulated activities were the wall of the small intestines, liver, urinary bladder wall, wall of the upper large intestine and the wall of the gallbladder.
Pet organa/tkiva s najvišim kumuliranim aktivnostima bili su stijenka tankog crijeva, jetra, zid mokraćnog mjehura, zid gornjeg debelog crijeva i zid žučnog mjehura.
The fixed dose combination tablet of pioglitazone 15 mg/metformin 850 mg BID (N=201), pioglitazone 15 mg BID (N=189), and metformin 850 mg BID (N=210) were evaluated in type 2 diabetes mellitus patients with mean baseline HbA1c of 9.5% in a randomised double-blind, parallel-group study.
Fiksna kombinacija pioglitazona u dozi od 15 mg i metformina u dozi od 850 mg dvaput na dan u tableti (N=201), pioglitazon u dozi od 15 mg dvaput na dan (N=189) i metformin u dozi od 850 mg dvaput na dan (N=210) ispitana je u randomiziranom, dvostruko slijepom ispitivanju na usporednim skupinama bolesnika sa šećernom bolešću tipa 2 i prosječnim početnim HbA1c od 9,5%.
The fixed dose combination tablet of pioglitazone 15 mg/metformin 850 mg BID (N=201), pioglitazone 15 mg BID (N=189), and metformin 850 mg BID (N=210) were evaluated in type 2 diabetes mellitus patients with mean baseline HbA1c of 9.5% in a randomised double-blind, parallel-group study.
Fiksna kombinacija pioglitazona u dozi od 15 mg i metformina u dozi od 850 mg dvaput na dan u tableti (N=201), pioglitazon u dozi od 15 mg dvaput na dan (N=189) i metformin u dozi od 850 mg dvaput na dan (N=210) ispitana je u randomiziranom, dvostruko slijepom ispitivanju na usporednim skupinama bolesnika sa šećernom bolešću tipa 2 i srednjom vrijednošću početnog HbA1c od 9,5%.
The fixed doses of Xeplion in these studies were given on days 1, 8, and 36 in the 9-week study, and additionally on day 64 of the 13-week studies.
Fiksne doze lijeka Xeplion u tim su ispitivanjima primijenjene 1., 8. i 36. dana u 9-tjednom ispitivanju te dodatno i 64. dana u 13- tjednom ispitivanju.
The FKBP12- tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium- dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of cytokine genes.
Kompleks FKBP12 i takrolimusa specifično se i kompetitivno veže za kalcineurin i inhibira ga, što dovodi do inhibicije signalnih puteva T-stanica ovisne o kalciju i sprječava prepisivanje diskretne skupine gena za citokine.
The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of cytokine genes.
Kompleks FKBP12 i takrolimusa specifično i kompetitivno se veže za kalcineurin te ga inhibira, što uzrokuje inhibiciju puteva transdukcije signala T-stanica ovisnih o kalciju, time se sprječava transkripcija posebne skupine gena za citokine.
The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of lymphokine genes.
Kompleks FKBP12-takrolimus specifično se i kompetitivno veže za kalcineurin i inhibira ga što dovodi do inhibicije signalnih puteva T-stanica ovisne o kalciju i tako sprječava prepisivanje odvojene skupine gena za limfokine.
The flange of the transfer device should rest on the surface of the stopper so that the solvent flows into the powder vial.
Izbočeni obod pomagala za prijenos treba se nasloniti na površinu čepa tako da otapalo teče u bočicu s praškom.
The flea field study found a 90% reduction in flea count in 96.7% and 88.7% of Trifexis-treated dogs at day 14 and 30 respectively, compared with 85.9% and 73.2% in the selamectin-treated dogs.
Terensko ispitivanje buha utvrdilo je 90%-tno smanje broja buha u 96,7% i 88,7% pasa liječenih VMP- om Trifexis 14., odnosno 30. dana, u usporedbi s 85,9% i 73,2% pasa liječenih selamektinom.
The flea preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the veterinary medicinal product.
Preventivno djelovanje protiv ponovljene infestacije buhama rezultat je adulticidnog djelovanja i smanjenja proizvodnje jajašaca u trajanju do 4 tjedna nakon jednokratne primjene ovog veterinarsko- medicinskog proizvoda.
The flea preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of this product.
Preventivno djelovanje protiv ponovljene infestacije buhama rezultat je adulticidnog djelovanja i smanjenja proizvodnje jajašaca i traje do 4 tjedna nakon jednokratne primjene ovog veterinarsko- medicinskog proizvoda.
The flip-off seal button colour is ivory for the 300 mg presentation and blue for the 400 mg presentation.
"Flip-off" kapica bočice od 300 mg je boje bjelokosti, dok je "flip-off" kapica bočice od 400 mg plave boje.
The Flixabi solution will be slowly injected (over a 2 hour period) into one of your veins.
Otopinu lijeka Flixabi ćete dobivati polagano (tijekom 2 sata) u jednu od vena.
the foetus to:
fetus izložiti:
the foetus to:
fetus:
The foil sachets are packaged in an outer carton.
Vrećice od folije su pakirane u kartonske kutije.
The folding box contains one vial with a lyophilised powder, one ready for use syringe with a solvent, one vial adapter and one needle.
Preklopiva kutija sadrži jednu bočicu s liofiliziranim praškom, jednu napunjenu štrcaljku s otapalom spremnu za primjenu, jedan nastavak za bočicu i jednu iglu.
The follitropin alfa in Bemfola, as well as in the reference product GONAL-f, is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce human FSH.
Folitropin alfa u lijeku Bemfola, kao i u referentnom lijeku GONAL-f, proizvodi se metodom poznatom pod nazivom „tehnologijom rekombinantne DNK”: proizvodi se od stanica u koje je umetnut gen (DNK), zbog čega stanice mogu proizvoditi ljudski FSH.
The follitropin alfa in Ovaleap, as well as in the reference product GONAL-f, is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced that makes them able to produce human FSH.
Folitropin alfa u lijeku Ovaleap, kao i u referentnom lijeku GONAL-f, proizvodi se metodom poznatom pod nazivom „tehnologijom rekombinantne DNK“: proizvodi se od stanica u koje je umetnut gen (DNK), zbog čega stanice mogu proizvoditi ljudski FSH.
The follow-up protocol
Protokol praćenja
The following actions have been demonstrated for endogenous human IGF-1:
Iskazana su sljedeća djelovanja za endogeni ljudski IGF-1:
The following active substances may affect the heart rhythm:
Sljedeće djelatne tvari mogu utjecati na srčani ritam:
The following active substances may increase the risk of side effects with Bosulif:
Sljedeće djelatne tvari mogu povećati rizik od nuspojava s Bosulifom:
The following active substances may reduce the effectiveness of Bosulif:
Sljedeće djelatne tvari mogu smanjiti učinkovitost Bosulifa:
The following activities should be avoided:
Sljedeće aktivnosti se moraju izbjegavati:
The following additional adverse events were reported from post-marketing surveillance with Focetria H1N1v (licensed for use from 6 months of age and with a composition that is similar to Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics):
Sljedeći dodatni štetni događaji prijavljeni su tijekom postmarketinškog praćenja H1N1v cjepiva Focetria (odobrenog za primjenu u dobi od 6 mjeseci i više te sastava sličnog Prepandemijskom cjepivu protiv influence (H5N1) (površinski antigen, inaktivirano, adjuvantirano) Novartis Vaccines and Diagnostics):
The following additional adverse events were reported from post-marketing surveillance with Focetria H1N1v (licensed for use in children 6 months of age and above, adults and the elderly with a composition that is similar to AFLUNOV):
Sljedeće dodatne nuspojave prijavljene su tijekom praćenja nakon stavljanja u promet lijeka Focetria H1N1v (odobrenog za primjenu u djece u dobnim skupinama od 6 mjeseci i starijima, odraslim i starijima osobama, a sastava sličnog cjepivu AFLUNOV):
The following additional adverse events were reported from post-marketing surveillance with seasonal non-adjuvanted trivalent vaccines in all age groups and a seasonal adjuvanted trivalent vaccine with a composition similar to AFLUNOV (surface antigen, inactivated, adjuvanted with MF59C.1) that is licensed for use in elderly subjects 65 years of age and older:
Sljedeće dodatne nuspojave prijavljene su tijekom praćenja nakon stavljanja u promet sezonskih neadjuvantiranih trovalentnih cjepiva u svim dobnim skupinama i sezonskog adjuvantiranog trovalentnog cjepiva sastava sličnog cjepivu AFLUNOV (površinski antigen, inaktivirano, adjuvantiran s MF59C.1) koje je odobreno za primjenu na starijim ispitanicima u dobi od 65 godina naviše: